AnaptysBio Inc ANAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $47.89
- Day Range
- $45.94–47.66
- 52-Week Range
- $19.66–72.19
- Bid/Ask
- $45.98 / $46.02
- Shares Outstanding
- 29.90M
- Market Cap
- $1.38B
- Volume/Avg
- 271,400 / 575,234
Key Statistics
- Price/Earnings (Normalized)
- 253.25
- Price/Sales
- 5.83
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 2.53%
Company Profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 104
- Website
- https://www.anaptysbio.com
Valuation
|
Metric
|
ANAB
|
|---|---|
Price/Earnings (Normalized) | 253.25 |
Price/Book Value | 134.50 |
Price/Sales | 5.83 |
Price/Cash Flow | 14.05 |
Price/Earnings
ANAB
Financial Strength
|
Metric
|
ANAB
|
|---|---|
Quick Ratio | 5.37 |
Current Ratio | 5.61 |
Interest Coverage | 2.70 |
Quick Ratio
ANAB
Profitability
|
Metric
|
ANAB
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ANAB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>KMrb@ | LOCK|?$&< | $127B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^x@R<m | LOCK|><Qd$ | $76B | |||
| Moderna Inc
MRNA
| LOCK|^^Lpy<B | LOCK|#L | $75B | |||
| argenx SE ADR
ARGX
| LOCK|<^xVK< | LOCK|q&% | $59B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|TpL@#bM | LOCK|Gkf | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%Gfqt> | LOCK|!<@r | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|GWv^F?dN | LOCK|qWt!r | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|MRB%$%l | LOCK|pH | $24B | |||
| Incyte Corp
INCY
| LOCK|$H?!!S | LOCK|Tw? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#jQp&% | LOCK|bS | $15B |
United States